Merck (known as MSD outside the U.S. and Canada) has announced that the U.S. Food and Drug Administration has approved IDVYNSO™, a once-daily, two-drug single-tablet regimen for adults with HIV-1. Clinicians can prescribe it to replace existing antiretroviral therapy in patients who are virologically suppressed (HIV-1 RNA <50 copies/mL) and have no history of treatment failure or resistance to doravirine.
A Simplified, Alternative Treatment Option
IDVYNSO combines doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), with islatravir, a next-generation nucleoside analog. Notably, it is the only two-drug, non-INSTI, tenofovir-free oral regimen currently available, thereby expanding treatment options for patients who may need to switch therapies.
However, clinicians must avoid co-administering the drug with strong CYP3A enzyme inducers, lamivudine, or emtricitabine, as these may reduce its effectiveness.
Strong Clinical Evidence Supports Approval
As reported by Merck’s Press release, the approval is based on two Phase 3 trials (Trial 051 and Trial 052) involving over 700 virologically suppressed adults. In both studies, patients who switched to IDVYNSO maintained viral suppression at rates comparable to those on standard regimens.
At Week 48, only 1% of participants on IDVYNSO showed viral loads ≥50 copies/mL, demonstrating non-inferior efficacy. Furthermore, suppression rates remained high—up to 96% in some groups—highlighting its reliability across diverse patient populations.
Safety Profile and Key Considerations
Overall, IDVYNSO demonstrated a safety profile comparable to existing therapies. Common side effects included diarrhea, dizziness, fatigue, headache, and mild weight changes. Importantly, discontinuation rates due to adverse events remained low.
Nevertheless, clinicians should monitor for rare but serious reactions, including Stevens-Johnson syndrome and DRESS. In addition, potential drug interactions require careful review before and during treatment.
Expanding HIV Care Options
As people with HIV live longer, treatment strategies must evolve to address ageing-related health challenges and medication burden. In this context, IDVYNSO offers a simplified and effective alternative for long-term management.
With availability expected after May 11, this approval marks a significant step forward in diversifying HIV treatment and improving patient-centric care.